Erin Clancy

Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.

Researchers say they have identified 4 subtypes of prostate cancer with distinct biological and clinical features, and these subtypes may respond differently to treatment.

Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.